Page last updated: 2024-12-08
sulfolipid i
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
sulfolipid I: principal sulfolipid class of virulent human Mycobacterium tuberculosis strain H(37)Rv [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
sulfolipid I : The principal sulfolipid class of virulent human Mycobacterium tuberculosis strain H(37)Rv. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 46878365 |
CHEBI ID | 26828 |
MeSH ID | M0053981 |
Synonyms (4)
Synonym |
---|
sulfolipid i |
6-o-[(2s,4s,6s,8s,10r,12r,14r,16r,17r)-17-hydroxy-2,4,6,8,10,12,14,16-octamethyldotriacontanoyl]-2-o-sulfo-alpha-d-glucopyranosyl 3-o-[(2s,4s,6s,8s,10r,12r,14r,16r,17r)-17-hydroxy-2,4,6,8,10,12,14,16-octamethyldotriacontanoyl]-6-o-[(2s,4s,6s,8s,10s,12s,14 |
2-palmitoyl-3-phthioceranoyl-6,6'-bis(hydroxyphthioceranoyl) trehalose-2'-sulfate |
CHEBI:26828 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
sulfoglycolipid | A sulfate ester of a glycolipid. |
polyacyl alpha,alpha-trehalose derivative | A glycolipid that is an alpha,alpha-trehalose derivative in which two or more of the trehalose hydroxy groups are acylated. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (13.64) | 18.7374 |
1990's | 2 (9.09) | 18.2507 |
2000's | 9 (40.91) | 29.6817 |
2010's | 7 (31.82) | 24.3611 |
2020's | 1 (4.55) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |